PDF(Pubmed)
Abstract：
Multidrug-resistant/extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa (PA) are critical antimicrobial resistance threats. Despite their increasing prevalence, treatment options for metallo-β-lactamase (MBL)-producing PA are limited, especially for New Delhi metallo-β-lactamase (NDM) producers. Pending further clinical studies, this case provides support for limited-scope use of cefepime-zidebactam for treating disseminated infections secondary to NDM-producing XDR PA. Susceptibilities should be tested and/or alternative regimens considered when treating isolates with alternative MBLs or increased efflux pump expression because some in vitro data suggest associated loss of cefepime-zidebactam susceptibility.
摘要：
多药耐药/广泛耐药（MDR/XDR）铜绿假单胞菌（PA）是关键的抗微生物耐药性威胁。尽管它们的患病率越来越高，产生金属β-内酰胺酶（MBL）的PA的治疗选择有限，特别是新德里金属β-内酰胺酶（NDM）生产商。在进一步的临床研究之前，本病例支持在有限范围内使用头孢吡肟-齐达巴坦治疗由NDM产生的XDRPA继发的播散性感染.当使用替代MBL或外排泵表达增加治疗分离株时，应测试敏感性和/或考虑替代方案，因为一些体外数据表明头孢吡肟-齐达巴坦敏感性相关丧失。
